Zomedica Corp   (ZOM)
Other Ticker:  
Price: $0.1550 $0.01 8.392%
Day's High: $0.1599 Week Perf: 26.53 %
Day's Low: $ 0.14 30 Day Perf: 15.76 %
Volume (M): 12,147 52 Wk High: $ 0.27
Volume (M$): $ 1,883 52 Wk Avg: $0.19
Open: $0.14 52 Wk Low: $0.12

 Market Capitalization (Millions $) 152
 Shares Outstanding (Millions) 980
 Employees -
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 14

Zomedica Corp
Zomedica Corp is a veterinary pharmaceutical company that develops and commercializes medical devices and drugs for pets. The company focuses on developing innovative solutions to enhance the overall healthcare of animals. Their products include diagnostics, therapeutics, and devices that aim to improve the diagnostic accuracy and treatment options for veterinarians. Zomedica Corp is committed to advancing animal health through their research and development efforts, as well as their partnerships with veterinarians and animal health companies.

   Company Address: 100 Phoenix Drive Ann Arbor 48108 MI
   Company Phone Number: 369-2555   Stock Exchange / Ticker: NYSE ZOM
   ZOM is expected to report next financial results on March 14, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Zomedica Corp

Zomedica Corp Achieves Record-breaking $5.362 Million Top-line in Q3 - Paving the Way for Success in 2023

Zomedica Corp, a major player in the field of pharmaceutical preparations, has recently reported its third-quarter earnings for 2023. While the company managed to achieve break-even on a per-share basis and witnessed a slight increase in revenue, several concerning factors indicate a potential decline in its overall business performance. This article aims to delve into the various reasons supporting a bearish outlook on Zomedica Corp.
Underwhelming Financial Performance:
ZOM's break-even earnings per share for Q3 2023, while an improvement compared to the previous year, remain lackluster. It is concerning that the company hasn't demonstrated significant growth in earnings despite operating in a market that witnessed a revenue gain of 12.27% in the same reporting season. This suggests that Zomedica Corp is struggling to capitalize on the growth potential in the Major Pharmaceutical Preparations sector.

Zomedica Corp

Zomedica Corp Smashes Expectations with Remarkable 18.888% Revenue Growth in Q2 2023

As an analyst covering the financial markets, I have been closely monitoring Zomedica Corp's recent financial results and its stock performance. The company's fiscal results for the time-frame ending June 30, 2023, have certainly raised eyebrows and sparked discussion within the investment community.
Zomedica Corp reported a loss of $-0.01 per share for the period, which is consistent with the previous year and the prior reporting period. While this may not have been unexpected, it is worth noting that Zomedica Corp managed to achieve a notable revenue increase of 18.888% compared to the same period a year ago. This is particularly impressive when considering the major pharmaceutical preparations industry's average contraction in revenue of -9.44%.

Zomedica Corp

Zomedica Corp's Surge in Revenue Fails to Make Company Profitable, Reporting Net Loss of $6.4 Million in Latest Financial Results

Zomedica Corp, a veterinary diagnostic and pharmaceutical company, has reported its financial results for its fiscal timeframe ending March 31, 2023. The company experienced a surge in revenue of 46.148%, reaching $5.48 million from the same period a year earlier. However, the company's net loss increased to $-6.385 million, up from $-3.937 million.
Despite the growth in revenue, Zomedica Corp experienced a loss per share of $-0.01 from the same time-frame a year prior when it reported zero earnings per share. The company's net loss also increased by over $2 million.


Zomedica's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com